Navigation Links
Aeras-led research consortium receives FDA support
Date:10/4/2010

Rockville, MD, USA (October 4, 2010) The Aeras Global TB Vaccine Foundation is pleased to announce receipt of a grant from the United States Food and Drug Administration (FDA) to develop new biological and immunological biomarkers for TB vaccine development. The FDA grant, which supports the coordination of a multi-investigator project with researchers from the United States, the United Kingdom and South Africa, will provide $362,102 in the first year of funding. The project is anticipated to cost $785,940 over three years.

"We are grateful for this show of support from the Food and Drug Administration for TB vaccine research," said Thomas G. Evans, MD, Chief Scientific Officer of the Aeras Global TB Vaccine Foundation. "Functional and biologically relevant immunological responses that correlate with vaccine efficacy remain elusive for tuberculosis so we are fortunate to be working with leaders in bioassay research to tackle this essential component of TB vaccine development."

The global TB epidemic continues to grow more complex and difficult to treat. The currently available TB vaccine called Bacille Calmette-Gurin has limited efficacy in preventing all forms of TB. BCG was developed before modern biotechnological advances and its method of eliciting immune response is not fully understood by researchers. Currently, there are 10 investigational TB vaccines designed as boosters or potential replacements for the BCG vaccine currently undergoing or poised to enter clinical testing and many more in the product development pipeline.

To effectively assess these and future investigational TB vaccines, biomarkers correlated with vaccine effectiveness are needed. A biomarker would facilitate clinical studies of vaccines across research institutions, geographic locations and within different target age groups and populations, standardizing and streamlining the regulatory review of clinical trial data.

"The development of biomarkers, particularly those that measure bacteriocidal effects correlated with TB vaccine effectiveness, could help shorten timeframes for introducing new TB vaccines, as we work with regulatory agencies like the FDA to conduct clinical trials and approve new TB vaccines," said Michael Brennan, PhD, Senior Advisor for Global Affairs at Aeras.

The project aims to evaluate four mycobacterial growth inhibition assays that can be reproducibly transferred to other laboratories and to identify T-cell immune and antibody responses that may be associated with ex vivo growth inhibition and potentially with protective vaccines.

The consortium is comprised of researchers at the Aeras Global TB Vaccine Foundation; the Jenner Institute, University of Oxford; the South African Tuberculosis Vaccine Initiative of the University of Cape Town; Saint Louis University; and Albert Einstein College of Medicine.


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras Global TB Vaccine Foundation
Source:Eurekalert

Related biology news :

1. McGill partners with leading Swiss neuroscience research group
2. Bonn researchers use light to make the heart stumble
3. Hebrew University research holds promise for development of new osteoporosis drug
4. Earlier, more accurate prediction of embryo survival enabled by Stanford research
5. Researchers engineer adult stem cells that do not age
6. Research becomes a reality for Rett syndrome through new funding
7. OU researchers selected by Navy
8. RIT receives federal grant to construct new sustainability research facility
9. Iowa State University researcher examines mosquito gene for new disease response
10. NIH awards Rutgers $47.5 million to advance groundbreaking research on protein structures
11. NIH Transformative Research Project Awards hasten innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
Breaking Biology Technology: